Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNE684
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Intra-arterial, Oral
01
Overview
GNE684 (also known as GNE-684) is a potent, selective, and orally active small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1, also known as RIP1). Developed by Genentech, GNE684 acts as a type III allosteric inhibitor, blocking RIPK1 kinase activity to prevent necroptosis and apoptosis. In preclinical models, GNE684 has demonstrated therapeutic efficacy in reducing inflammation and tissue damage associated with colitis, ileitis, collagen antibody-induced arthritis, dermatitis, graft-versus-host disease (GVHD), and kidney ischemia-reperfusion injury (IRI).
- Other names
- (5S)-N-[(3S)-7-methoxy-1-methyl-2-oxo-4,5-dihydro-3H-pyrido[3,4-b]azepin-3-yl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamideGNE 684GNE684GNE-684
02
Targets
RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)
Beyond the preview
Go deeper on GNE684.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNE684.